Modeling HIV persistence, the latent reservoir, and viral blips

Journal of Theoretical Biology

Volumn 260, Issue 2, 2009, Pages 308-331

  Rong, Libin ^a   Perelson, Alan S ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

Blips; HAART; HIV 1; Latency; Low level viremia; Mathematical models; Viral reservoirs

Indexed keywords

ALPHA INTERFERON; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; ENFUVIRTIDE; INTERLEUKIN 2; INTERLEUKIN 6; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; OKT 3; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

DISEASE PREVALENCE; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS; MATHEMATICAL ANALYSIS; MODELING; NUMERICAL MODEL;

ANTIVIRAL RESISTANCE; BYSTANDER EFFECT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DRUG INTERMITTENT THERAPY; EARLY INTERVENTION; ERADICATION THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; MATHEMATICAL MODEL; MEMORY T LYMPHOCYTE; MULTIDRUG RESISTANCE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROBABILITY; REVIEW; SALVAGE THERAPY; SEROCONVERSION; T LYMPHOCYTE ACTIVATION; VIRAL BLIP; VIREMIA; VIRION; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; VIRAL LOAD; VIREMIA; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 68949196315     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2009.06.011     Document Type: Review

References (237)

1. Adams B.M., Banks H.T., Davidian M., and Rosenberg E.S. Estimation and prediction with HIV-treatment interruption data. Bull. Math. Biol. 69 (2007) 563-584
2. Ahmed R., and Gray D. Immunological memory and protective immunity: understanding their relation. Science 272 (1996) 54-60
3. Bailey J.R., Sedaghat A.R., Kieffer T., Brennan T., Lee P.K., Wind-Rotolo M., Haggerty C.M., Kamireddi A.R., Liu Y., Lee J., Persaud D., Gallant J.E., Cofrancesco Jr. J., Quinn T.C., Wilke C.O., Ray S.C., Siliciano J.D., Nettles R.E., and Siliciano R.F. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD 4 + T cells. J. Virol. 80 (2006) 6441-6457
4. Bajaria S.H., Webb G., and Kirschner D.E. Predicting differential responses to structured treatment interruptions during HAART. Bull. Math. Biol. 66 (2004) 1093-1118
5. Benson C.A. Structured treatment interruptions-new findings. Top. HIV Med. 14 (2006) 107-111
6. Birk M., Aleman S., Visco-Comandini U., and Sonnerborg A. Proviral HIV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy. HIV Med. 1 (2000) 205-211
7. Blankson J.N., Finzi D., Pierson T.C., Sabundayo B.P., Chadwick K., Margolick J.B., Quinn T.C., and Siliciano R.F. Biphasic decay of latently infected CD 4 + T cells in acute human immunodeficiency virus type 1 infection. J. Infect. Dis. 182 (2000) 1636-1642
8. Blankson J.N., Persaud D., and Siliciano R.F. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53 (2002) 557-593
9. Blankson J.N., Siliciano J.D., and Siliciano R.F. The effect of early treatment on the latent reservoir of HIV-1. J. Infect. Dis. 191 (2005) 1394-1396
10. Bonhoeffer S., Coffin J.M., and Nowak M.A. Human immunodeficiency virus drug therapy and virus load. J. Virol. 71 (1997) 3275-3278
11. Bonhoeffer S., May R.M., Shaw G.M., and Nowak M.A. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA 94 (1997) 6971-6976
12. Bonhoeffer S., and Nowak M.A. Pre-existence and emergence of drug resistance in HIV-1 infection. Proc. R. Soc. London B 264 (1997) 631-637
13. Bucy R.P. Immune clearance of HIV type 1 replication-active cells: a model of two patterns of steady state HIV infection. AIDS Res. Hum. Retroviruses 15 (1999) 223-227
14. Callaway D.S., and Perelson A.S. HIV-1 infection and low steady state viral loads. Bull. Math. Biol. 64 (2002) 29-64
15. Chang J.T., Palanivel V.R., Kinjyo I., Schambach F., Intlekofer A.M., Banerjee A., Longworth S.A., Vinup K.E., Mrass P., Oliaro J., Killeen N., Orange J.S., Russell S.M., Weninger W., and Reiner S.L. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 315 (2007) 1687-1691
16. Chen H.Y., Di Mascio M., Perelson A.S., Ho D.D., and Zhang L. Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc. Natl. Acad. Sci. USA 104 (2007) 19079-19084
17. Ching N., Yang O.O., Deville J.G., Nielsen-Saines K., Ank B.J., Sim M.S., and Bryson Y.J. Pediatric HIV-1-specific cytotoxic T-lymphocyte responses suggesting ongoing viral replication despite combination antiretroviral therapy. Pediatr. Res. 61 (2007) 692-697
18. Chomont, N., et al., 2009. HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferaiton. Nat. Med., in press, doi:10.1038/nm.1972.
19. Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T.C., Kuo Y.H., Brookmeyer R., Zeiger M.A., Barditch-Crovo P., and Siliciano R.F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387 (1997) 183-188
20. Chun T.W., Stuyver L., Mizell S.B., Ehler L.A., Mican J.A., Baseler M., Lloyd A.L., Nowak M.A., and Fauci A.S. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94 (1997) 13193-13197
21. Chun T.W., Davey Jr. R.T., Engel D., Lane H.C., and Fauci A.S. Re-emergence of HIV after stopping therapy. Nature 401 (1999) 874-875
22. Chun T.W., Engel D., Mizell S.B., Hallahan C.W., Fischette M., Park S., Davey Jr. R.T., Dybul M., Kovacs J.A., Metcalf J.A., Mican J.M., Berrey M.M., Corey L., Lane H.C., and Fauci A.S. Effect of interleukin-2 on the pool of latently infected, resting CD 4 + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5 (1999) 651-655
23. Chun T.W., Davey Jr. R.T., Ostrowski M., Shawn Justement J., Engel D., Mullins J.I., and Fauci A.S. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6 (2000) 757-761
24. Chun T.W., Engel D., Berrey M.M., Shea T., Corey L., and Fauci A.S. Early establishment of a pool of latently infected, resting CD 4 (+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95 (1998) 8869-8873
25. Chun T.W., Engel D., Mizell S.B., Ehler L.A., and Fauci A.S. Induction of HIV-1 replication in latently infected CD 4 + T cells using a combination of cytokines. J. Exp. Med. 188 (1998) 83-91
26. Chun T.W., and Fauci A.S. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. USA 96 (1999) 10958-10961
27. Chun T.W., Finzi D., Margolick J., Chadwick K., Schwartz D., and Siliciano R.F. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1 (1995) 1284-1290
28. Chun T.W., Justement J.S., Moir S., Hallahan C.W., Maenza J., Mullins J.I., Collier A.C., Corey L., and Fauci A.S. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J. Infect. Dis. 195 (2007) 1762-1764
29. Chun T.W., Justement J.S., Pandya P., Hallahan C.W., McLaughlin M., Liu S., Ehler L.A., Kovacs C., and Fauci A.S. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD 4 + T cells and CD 4 +:CD 8 + T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J. Infect. Dis. 185 (2002) 1672-1676
30. Chun T.W., Nickle D.C., Justement J.S., Large D., Semerjian A., Curlin M.E., O'Shea M.A., Hallahan C.W., Daucher M., Ward D.J., Moir S., Mullins J.I., Kovacs C., and Fauci A.S. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115 (2005) 3250-3255
31. Clavel F., and Hance A.J. HIV drug resistance. N. Engl. J. Med. 350 (2004) 1023-1035
32. Cocohoba J., and Dong B.J. Raltegravir: the first HIV integrase inhibitor. Clin. Ther. 30 (2008) 1747-1765
33. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267 (1995) 483-489
34. Cohen Stuart J.W., Wensing A.M., Kovacs C., Righart M., de Jong D., Kaye S., Schuurman R., Visser C.J., and Boucher C.A. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J. Acquir. Immune Defic. Syndr. 28 (2001) 105-113
35. Collier A.C., Coombs R.W., Schoenfeld D.A., Bassett R.L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V.J., Friedman H.M., Merigan T.C., Reichman R.C., Hooper C., and Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med. 334 (1996) 1011-1017
36. Davey Jr. R.T., Bhat N., Yoder C., Chun T.W., Metcalf J.A., Dewar R., Natarajan V., Lempicki R.A., Adelsberger J.W., Miller K.D., Kovacs J.A., Polis M.A., Walker R.E., Falloon J., Masur H., Gee D., Baseler M., Dimitrov D.S., Fauci A.S., and Lane H.C. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96 (1999) 15109-15114
37. De Boer R.J. Understanding the failure of CD 8 + T-cell vaccination against simian/human immunodeficiency virus. J. Virol. 81 (2007) 2838-2848
38. De Boer R.J., Ganusov V.V., Milutinovic D., Hodgkin P.D., and Perelson A.S. Estimating lymphocyte division and death rates from CFSE data. Bull. Math. Biol. 68 (2006) 1011-1031
39. De Boer R.J., Homann D., and Perelson A.S. Different dynamics of CD 4 + and CD 8 + T cell responses during and after acute lymphocytic choriomeningitis virus infection. J. Immunol. 171 (2003) 3928-3935
40. De Boer R.J., Oprea M., Antia R., Murali-Krishna K., Ahmed R., and Perelson A.S. Recruitment times, proliferation, and apoptosis rates during the CD 8 (+) T-cell response to lymphocytic choriomeningitis virus. J. Virol. 75 (2001) 10663-10669
41. De Boer R.J., and Perelson A.S. Target cell limited and immune control models of HIV infection: a comparison. J. Theor. Biol. 190 (1998) 201-214
42. De Boer R.J., and Perelson A.S. Estimating division and death rates from CFSE data. J. Comput. Appl. Math. 184 (2005) 140-164
43. Deeks S.G., Wrin T., Liegler T., Hoh R., Hayden M., Barbour J.D., Hellmann N.S., Petropoulos C.J., McCune J.M., Hellerstein M.K., and Grant R.M. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344 (2001) 472-480
44. Devereux H.L., Youle M., Johnson M.A., and Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13 (1999) 123-127
45. Di Mascio M., Markowitz M., Louie M., Hogan C., Hurley A., Chung C., Ho D.D., and Perelson A.S. Viral blip dynamics during highly active antiretroviral therapy. J. Virol. 77 (2003) 12165-12172
46. Di Mascio M., Markowitz M., Louie M., Hurley A., Hogan C., Simon V., Follmann D., Ho D.D., and Perelson A.S. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. J. Virol. 78 (2004) 10566-10573
47. Di Mascio M., Percus J.K., Percus O.E., Markowitz M., Ho D.D., and Perelson A.S. Duration of an intermittent episode of viremia. Bull. Math. Biol. 67 (2005) 885-900
48. Di Mascio M., Ribeiro R.M., Markowitz M., Ho D.D., and Perelson A.S. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math. Biosci. 188 (2004) 47-62
49. Dimitrov D.S., Willey R.L., Sato H., Chang L.J., Blumenthal R., and Martin M.A. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 67 (1993) 2182-2190
50. Dinoso J.B., Kim S.Y., Wiegand A.M., Palmer S.E., Gange S.J., Cranmer L., O'Shea A., Callender M., Spivak A., Brennan T., Kearney M.F., Proschan M.A., Mican J.M., Rehm C.A., Coffin J.M., Mellors J.W., Siliciano R.F., and Maldarelli F. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 106 (2009) 9403-9408
51. Dornadula G., Zhang H., VanUitert B., Stern J., Livornese Jr. L., Ingerman M.J., Witek J., Kedanis R.J., Natkin J., DeSimone J., and Pomerantz R.J. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282 (1999) 1627-1632
52. Duh E.J., Maury W.J., Folks T.M., Fauci A.S., and Rabson A.B. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc. Natl. Acad. Sci. USA 86 (1989) 5974-5978
53. Dybul M., Daucher M., Jensen M.A., Hallahan C.W., Chun T.W., Belson M., Hidalgo B., Nickle D.C., Yoder C., Metcalf J.A., Davey R.T., Ehler L., Kress-Rock D., Nies-Kraske E., Liu S., Mullins J.I., and Fauci A.S. Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy. J. Virol. 77 (2003) 3229-3237
54. Ferguson N.M., deWolf F., Ghani A.C., Fraser C., Donnelly C.A., Reiss P., Lange J.M., Danner S.A., Garnett G.P., Goudsmit J., and Anderson R.M. Antigen-driven CD 4 + T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 96 (1999) 15167-15172
55. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C., Quinn T.C., Chaisson R.E., Rosenberg E., Walker B., Gange S., Gallant J., and Siliciano R.F. Latent infection of CD 4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5 (1999) 512-517
56. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., and Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 (1997) 1295-1300
57. Finzi D., and Siliciano R. Viral dynamics in HIV-1 infection. Cell 93 (1998) 665-671
58. Fischer M., Hafner R., Schneider C., Trkola A., Joos B., Joller H., Hirschel B., Weber R., Gunthard H.F., and Swiss HIV Cohort Study. HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS 17 (2003) 195-199
59. Fraser C., Ferguson N.M., and Anderson R.M. Quantification of intrinsic residual viral replication in treated HIV-infected patients. Proc. Natl. Acad. Sci. USA 98 (2001) 15167-15172
60. Fraser C., Ferguson N.M., de Wolf F., and Anderson R.M. The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications. Proc. Biol. Sci. 268 (2001) 2085-2095
61. Fraser J.D., and Proft T. The bacterial superantigen and superantigen-like proteins. Immunol. Rev. 225 (2008) 226-243
62. Frenkel L.M., Wang Y., Learn G.H., McKernan J.L., Ellis G.M., Mohan K.M., Holte S.E., De Vange S.M., Pawluk D.M., Melvin A.J., Lewis P.F., Heath L.M., Beck I.A., Mahalanabis M., Naugler W.E., Tobin N.H., and Mullins J.I. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J. Virol. 77 (2003) 5721-5730
63. Furtado M.R., Callaway D.S., Phair J.P., Kunstman K.J., Stanton J.L., Macken C.A., Perelson A.S., and Wolinsky S.M. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340 (1999) 1614-1622
64. Geeraert L., Kraus G., and Pomerantz R.J. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu. Rev. Med. 59 (2008) 215-229
65. Gett A.V., and Hodgkin P.D. A cellular calculus for signal integration by T cells. Nat. Immunol. 1 (2000) 239-244
66. Greub G., Cozzi-Lepri A., Ledergerber B., Staszewski S., Perrin L., Miller V., Francioli P., Furrer H., Battegay M., Vernazza P., Bernasconi E., Gunthard H.F., Hirschel B., Phillips A.N., Telenti A., and Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 16 (2002) 1967-1969
67. Grossman Z., Feinberg M., Kuznetsov V., Dimitrov D., and Paul W. HIV infection: how effective is drug combination treatment?. Immunol. Today 19 (1998) 528-532
68. Grossman Z., Polis M., Feinberg M.B., Grossman Z., Levi I., Jankelevich S., Yarchoan R., Boon J., de Wolf F., Lange J.M., Goudsmit J., Dimitrov D.S., and Paul W.E. Ongoing HIV dissemination during HAART. Nat. Med. 5 (1999) 1099-1104
69. Gulick R.M. Structured treatment interruption in patients infected with HIV. Drugs 62 (2002) 245-253
70. Gulick R.M., Lalama C.M., Ribaudo H.J., Shikuma C.M., Schackman B.R., Schouten J., Squires K.E., Koletar S.L., Pilcher C.D., Reichman R.C., Klingman K.L., and Kuritzkes D.R. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS 21 (2007) 813-823
71. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Meibohm A., Emini E.A., and Chodakewitz J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337 (1997) 734-739
72. Gunthard H.F., Frost S.D., Leigh-Brown A.J., Ignacio C.C., Kee K., Perelson A.S., Spina C.A., Havlir D.V., Hezareh M., Looney D.J., Richman D.D., and Wong J.K. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J. Virol. 73 (1999) 9404-9412
73. Gunthard H.F., Wong J.K., Ignacio C.C., Guatelli J.C., Riggs N.L., Havlir D.V., and Richman D.D. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J. Virol. 72 (1998) 2422-2428
74. Gunthard H.F., Wong J.K., Spina C.A., Ignacio C., Kwok S., Christopherson C., Hwang J., Haubrich R., Havlir D., and Richman D.D. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J. Infect. Dis. 181 (2000) 522-531
75. Haase A.T., Henry K., Zupancic M., Sedgewick G., Faust R.A., Melroe H., Cavert W., Gebhard K., Staskus K., Zhang Z.Q., Dailey P.J., Balfour Jr. H.H., Erice A., and Perelson A.S. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274 (1996) 985-989
76. Haggerty C.M., Pitt E., and Siliciano R.F. The latent reservoir for HIV-1 in resting CD 4 + T cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials. Curr. Opin. HIV AIDS 1 (2006) 62-68
77. Hall P.A., and Watt F.M. Stem cells: the generation and maintenance of cellular diversity. Development 106 (1989) 619-633
78. Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron Jr. J.J., Feinberg J.E., Balfour Jr. H.H., Deyton L.R., Chodakewitz J.A., and Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337 (1997) 725-733
79. Han Y., Lassen K., Monie D., Sedaghat A.R., Shimoji S., Liu X., Pierson T.C., Margolick J.B., Siliciano R.F., and Siliciano J.D. Resting CD 4 + T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78 (2004) 6122-6133
80. Havlir D.V., Bassett R., Levitan D., Gilbert P., Tebas P., Collier A.C., Hirsch M.S., Ignacio C., Condra J., Günthard H.F., Richman D.D., and Wong J.K. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 286 (2001) 171-179
81. Havlir D.V., Strain M.C., Clerici M., Ignacio C., Trabattoni D., Ferrante P., and Wong J.K. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J. Virol. 77 (2003) 11212-11219
82. Hawkins E.D., Turner M.L., Dowling M.R., van Gend C., and Hodgkin P.D. A model of immune regulation as a consequence of randomized lymphocyte division and death times. Proc. Natl. Acad. Sci. USA 104 (2007) 5032-5037
83. Hermankova M., Ray S.C., Ruff C., Powell-Davis M., Ingersoll R., D'Aquila R.T., Quinn T.C., Siliciano J.D., Siliciano R.F., and Persaud D. HIV-1 drug resistance profiles in children and adults with viral load of < 50 copies / ml receiving combination therapy. JAMA 286 (2001) 196-207
84. Hermankova M., Siliciano J.D., Zhou Y., Monie D., Chadwick K., Margolick J.B., Quinn T.C., and Siliciano R.F. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD 4 + T lymphocytes in vivo. J. Virol. 77 (2003) 7383-7392
85. Hlavacek W.S., Stilianakis N.I., Notermans D.W., Danner S.A., and Perelson A.S. Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proc. Natl. Acad. Sci. USA 97 (2000) 10966-10971
86. Hlavacek W.S., Stilianakis N.I., and Perelson A.S. Influence of follicular dendritic cells on HIV dynamics. Philos. Trans. R. Soc. London B Biol. Sci. 355 (2000) 1051-1058
87. Hlavacek W.S., Wofsy C., and Perelson A.S. Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis. Proc. Natl. Acad. Sci. USA 96 (1999) 14681-14686
88. Ho D.D. Viral counts count in HIV infection. Science 272 (1996) 1124-1125
89. Ho D.D. Toward HIV eradication or remission: the tasks ahead. Science 280 (1998) 1866-1867
90. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., and Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 (1995) 123-126
91. Ho D., Rota T., and Hirsch M. Infection of monocyte/macrophages by human T lymphotropic virus type III. J. Clin. Invest. 77 (1986) 1712-1715
92. Hockett R.D., Kilby J.M., Derdeyn C.A., Saag M.S., Sillers M., Squires K., Chiz S., Nowak M.A., Shaw G.M., and Bucy R.P. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J. Exp. Med. 189 (1999) 1545-1554
93. Holte S.E., Melvin A.J., Mullins J.I., Tobin N.H., and Frenkel L.M. Density-dependent decay in HIV-1 dynamics. J. Acquir. Immune Defic. Syndr. 41 (2006) 266-276
94. Homann D., Teyton L., and Oldstone M.B. Differential regulation of antiviral T-cell immunity results in stable CD 8 + but declining CD 4 + T-cell memory. Nat. Med. 7 (2001) 913-919
95. Horvitz H.R., and Herskowitz I. Mechanisms of asymmetric cell division: two Bs or not two Bs, that is the question. Cell 68 (1992) 237-255
96. Imamichi H., Crandall K.A., Natarajan V., Jiang M.K., Dewar R.L., Berg S., Gaddam A., Bosche M., Metcalf J.A., Davey Jr. R.T., and Lane H.C. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J. Infect. Dis. 183 (2001) 36-50
97. Jan Y.N., and Jan L.Y. Asymmetric cell division. Nature 392 (1998) 775-778
98. Jeffrey A.M., and Xia X. Identifiability of HIV/AIDS model. In: Tan W.Y., and Wu H. (Eds). Deterministic and Stochastic Models of AIDS Epidemics and HIV Infections with Intervention (2005), World Scientific, Singapore
99. Jones L.E., and Perelson A.S. Modeling the effects of vaccination on chronically infected HIV-positive patients. J. Acquir. Immune Defic. Syndr. 31 (2002) 369-377
100. Jones L.E., and Perelson A.S. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull. Math. Biol. 67 (2005) 1227-1251
101. Jones L.E., and Perelson A.S. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 45 (2007) 483-493
102. Jordan A., Bisgrove D., and Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22 (2003) 1868-1877
103. Kaech S.M., and Ahmed R. Memory CD 8 + T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2 (2001) 415-422
104. Kao S.Y., Calman A.F., Luciw P.A., and Peterlin B.M. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330 (1987) 489-493
105. Kepler T.B., and Perelson A.S. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc. Natl. Acad. Sci. USA 95 (1998) 11514-11519
106. Kieffer T.L., Finucane M.M., Nettles R.E., Quinn T.C., Broman K.W., Ray S.C., Persaud D., and Siliciano R.F. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 189 (2004) 1452-1465
107. Kim H., and Perelson A.S. Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput. Biol. 2 (2006) e135
108. Kim H., and Perelson A.S. Dynamic characteristics of HIV-1 reservoirs. Curr. Opin. HIV AIDS 1 (2006) 152-156
109. Kirschner D.E., and Webb G.F. Understanding drug resistance for montherapy treatment of HIV infection. Bull. Math. Biol. 59 (1997) 763-786
110. Kolber M.A., Campo R.E., and Dickinson G.M. Development of anti-retroviral resistance of HIV-1 infected individuals on therapy: is it inevitable?. IUBMB Life 56 (2004) 301-307
111. Korin Y.D., Brooks D.G., Brown S., Korotzer A., and Zack J.A. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol. 76 (2002) 8118-8123
112. Krakovska O., and Wahl L.M. Drug-sparing regimens for HIV combination therapy: benefits predicted for "drug coasting". Bull. Math. Biol. 69 (2007) 2627-2647
113. Kulkosky J., Culnan D.M., Roman J., Dornadula G., Schnell M., Boyd M.R., and Pomerantz R.J. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98 (2001) 3006-3015
114. Kupfer B., Matz B., Daumer M.P., Roden F., Rockstroh J.K., Qurishi N., Spengler U., and Kaiser R. Frequent detection of cell-associated HIV-1 RNA in patients with plasma viral load < 50 copies / ml. J. Med. Virol. 79 (2007) 1440-1445
115. Lafeuillade A., Poggi C., Chadapaud S., Hittinger G., Chouraqui M., Pisapia M., and Delbeke E. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. J. Acquir. Immune Defic. Syndr. 26 (2001) 44-55
116. Lambotte O., Chaix M.L., Gubler B., Nasreddine N., Wallon C., Goujard C., Rouzioux C., Taoufik Y., and Delfraissy J.F. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 18 (2004) 1147-1158
117. Langford D., Marquie-Beck J., de Almeida S., Lazzaretto D., Letendre S., Grant I., McCutchan J.A., Masliah E., and Ellis R.J. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J. Neurovirol. 12 (2006) 100-107
118. Lassen K., Han Y., Zhou Y., Siliciano J., and Siliciano R.F. The multifactorial nature of HIV-1 latency. Trends Mol. Med. 10 (2004) 525-531
119. Lawrence J., Hullsiek K.H., Thackeray L.M., Abrams D.I., Crane L.R., Mayers D.L., Jones M.C., Saldanha J.M., Schmetter B.S., and Baxter J.D. Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study. J. Acquir. Immune Defic. Syndr. 43 (2006) 169-178
120. Layne S.P., et al. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 189 (1992) 695-714
121. Lee H.Y., and Perelson A.S. Modeling T cell proliferation and death in vitro based on labeling data: generalizations of the Smith-Martin cell cycle model. Bull. Math. Biol. 70 (2008) 21-44
122. Lee P.K., Kieffer T.L., Siliciano R.F., and Nettles R.E. HIV-1 viral load blips are of limited clinical significance. J. Antimicrob. Chemother. 57 (2006) 803-805
123. Lehrman G., Hogue I.B., Palmer S., Jennings C., Spina C.A., Wiegand A., Landay A.L., Coombs R.W., Richman D.D., Mellors J.W., Coffin J.M., Bosch R.J., and Margolis D.M. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366 (2005) 549-555
124. Little S.J., McLean A.R., Spina C.A., Richman D.D., and Havlir D.V. Viral dynamics of acute HIV-1 infection. J. Exp. Med. 190 (1999) 841-850
125. Liu S.L., Rodrigo A.G., Shankarappa R., Learn G.H., Hsu L., Davidov O., Zhao L.P., and Mullins J.I. HIV quasispecies and resampling. Science 273 (1996) 415-416
126. Lori F., Foli A., and Lisziewicz J. Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects. J. Antimicrob. Chemother. 50 (2002) 155-160
127. Lori F., Jessen H., Lieberman J., Finzi D., Rosenberg E., Tinelli C., Walker B., Siliciano R.F., and Lisziewicz J. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J. Infect. Dis. 180 (1999) 1827-1832
128. Lori F., and Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA 286 (2001) 2981-2987
129. MacArthur R.D., and Novak R.M. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis. 47 (2008) 236-241
130. Macias J., Palomares J.C., Mira J.A., Torres M.J., Garcia-Garcia J.A., Rodriquez J.M., Vergera S., and Pineda J.A. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J. Infect. 51 (2005) 195-200
131. Maldarelli F., Palmer S., King M.S., Wiegand A., Polis M.A., Mican J., Kovacs J.A., Davey R.T., Rock-Kress D., Dewar R., Liu S., Metcalf J.A., Rehm C., Brun S.C., Hanna G.J., Kempf D.J., Coffin J.M., and Mellors J.W. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 3 (2007) e46
132. Margolis D.M., and Archin N.M. Eliminating persistent HIV infection: getting to the end of the rainbow. J. Infect. Dis. 195 (2007) 1734-1736
133. Markowitz M., Jin X., Hurley A., Simon V., Ramratnam B., Louie M., Deschenes G.R., Ramanathan Jr. M., Barsoum S., Vanderhoeven J., He T., Chung C., Murray J., Perelson A.S., Zhang L., and Ho D.D. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J. Infect. Dis. 186 (2002) 634-643
134. Markowitz M., et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46 (2007) 125-133
135. Marsden M.D., and Zack J.A. Eradication of HIV: current challenges and new directions. J. Antimicrob. Chemother. 63 (2009) 7-10
136. Martinez M.A., Cabana M., Ibanez A., Clotet B., Arno A., and Ruiz L. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 256 (1999) 180-187
137. Martinez V., Marcelin A.G., Morini J.P., Deleuze J., Krivine A., Gorin I., Yerly S., Perrin L., Peytavin G., Calvez V., and Dupin N. HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 19 (2005) 1065-1069
138. Martinez-Picado J., DePasquale M.P., Kartsonis N., Hanna G.J., Wong J., Finzi D., Rosenberg E., Gunthard H.F., Sutton L., Savara A., Petropoulos C.J., Hellmann N., Walker B.D., Richman D.D., Siliciano R., and D'Aquila R.T. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl. Acad. Sci. USA 97 (2000) 10948-10953
139. McCormick J.K., Yarwood J.M., and Schlievert P.M. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol. 55 (2001) 77-104
140. McLean A.R., and Michie C.A. In vivo estimates of division and death rates of human T lymphocytes. Proc. Natl. Acad. Sci. USA 92 (1995) 3707-3711
141. McLean A.R., and Nowak M.A. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS 6 (1992) 71-79
142. McLean A.R., and Nowak M.A. Models of interactions between HIV and other pathogens. J. Theor. Biol. 155 (1992) 69-86
143. Mellors J.W., Rinaldo Jr. C.R., Gupta P., White R.M., Todd J.A., and Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 (1996) 1167-1170
144. Michie C.A., Mclean A.R., Alcock C., and Beverley P.C. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 360 (1992) 264-265
145. Miller V., Sabin C., Hertogs K., Bloor S., Martinez-Picado J., D'Aquila R., Larder B., Lutz T., Gute P., Weidmann E., Rabenau H., Phillips A., and Staszewski S. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14 (2000) 2857-2867
146. Mira J.A., Macias J., Nogales C., Fernandez-Rivera J., Garcia-Garcia J.A., Ramos A., and Pineda J.A. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir. Ther. 7 (2002) 251-256
147. Mittler J.E., Markowitz M., Ho D.D., and Perelson A.S. Refined estimates for HIV-1 clearance rate and intracellular delay. AIDS 13 (1999) 1415-1417
148. Monie D., Simmons R.P., Nettles R.E., Kieffer T.L., Zhou Y., Zhang H., Karmon S., Ingersoll R., Chadwick K., Zhang H., Margolick J.B., Quinn T.C., Ray S.C., Wind-Rotolo M., Miller M., Persaud D., and Siliciano R.F. A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD 4 + T cells of viremic patients. J. Virol. 79 (2005) 5185-5202
149. Muller V., Vigueras-Gomez J.F., and Bonhoeffer S. Decelerating decay of latently infected cells during prolonged therapy for human immunodeficiency virus type 1 infection. J. Virol. 76 (2002) 8963-8965
150. Murphy E.L., Collier A.C., Kalish L.A., Assmann S.F., Para M.F., Flanigan T.P., Kumar P.N., Mintz L., Wallach F.R., Nemo G.J., and Viral Activation Transfusion Study Investigators. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 135 (2001) 17-26
151. Murray J.M., Emery S., Kelleher A.D., Law M., Chen J., Hazuda D.J., Nguyen B.Y., Teppler H., and Cooper D.A. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 21 (2007) 2315-2321
152. Murray J.M., and Perelson A.S. Human immunodeficiency virus: quasi-species and drug resistance. Multiscale Model. Simul. 3 (2005) 300-311
153. Nabel G., and Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326 (1987) 711-713
154. Natarajan V., Bosche M., Metcalf J.A., Ward D.J., Lane H.C., and Kovacs J.A. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet 353 (1999) 119-120
155. Nelson P.W., and Perelson A.S. Mathematical analysis of delay differential equation models of HIV-1 infection. Math. Biosci. 179 (2002) 73-94
156. Nettles R.E., Kieffer T.L., Kwon P., Monie D., Han Y., Parsons T., Cofrancesco Jr. J., Gallant J.E., Quinn T.C., Jackson B., Flexner C., Carson K., Ray S., Persaud D., and Siliciano R.F. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 293 (2005) 817-829
157. Nettles R.E., Kieffer T.L., Simmons R.P., Cofrancesco Jr. J., Moore R.D., Gallant J.E., Persaud D., and Siliciano R.F. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin. Infect. Dis. 39 (2004) 1030-1037
158. Noë A., Plum J., and Verhofstede C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J. Antimicrob. Chemother. 55 (2005) 410-412
159. Nowak M.A., and Bangham C.R. Population dynamics of immune responses to persistent viruses. Science 272 (1996) 74-79
160. Nowak M.A., Bonhoeffer S., Shaw G.M., and May R.M. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 184 (1997) 203-217
161. Nowak M.A., and May R.M. Virus Dynamics: Mathematical Principles of Immunology and Virology (2000), Oxford University Press, Oxford
162. Oxenius A., Price D.A., Easterbrook P.J., O'Callaghan C.A., Kelleher A.D., Whelan J.A., Sontag G., Sewell A.K., and Phillips R.E. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD 8 + and CD 4 + T lymphocytes. Proc. Natl. Acad. Sci. USA 97 (2000) 3382-3387
163. Palmer S., Maldarelli F., Wiegand A., Bernstein B., Hanna G.J., Brun S.C., Kempf D.J., Mellors J.W., Coffin J.M., and King M.S. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 105 (2008) 3879-3884
164. Palmer S., Wiegand A.P., Maldarelli F., Bazmi H., Mican J.M., Polis M., Dewar R.L., Planta A., Liu S., Metcalf J.A., Mellors J.W., and Coffin J.M. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41 (2003) 4531-4536
165. Parera M., Ibanez A., Clotet B., and Martinez M.A. Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy. J. Infect. Dis. 189 (2004) 1444-1451
166. Pariente N., Pernas M., de la Rosa R., Gomez-Mariano G., Fernandez G., Rubio A., Lopez M., Benito J.M., Lopez-Galindez C., Leal M., Domingo E., Martinez M.A., and Mas A. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes. J. Med. Virol. 73 (2004) 350-361
167. Patterson B.K., McCallister S., Schutz M., Siegel J.N., Shults K., Flener Z., and Landay A. Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS 15 (2001) 1635-1641
168. Percus J.K., Percus O.E., Markowitz M., Ho D.D., Di Mascio M., and Perelson A.S. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull. Math. Biol. 65 (2003) 263-277
169. Perelson A.S. Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2 (2002) 28-36
170. Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., Markowitz M., and Ho D.D. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387 (1997) 188-191
171. Perelson A.S., Essunger P., and Ho D.D. Dynamics of HIV-1 and CD 4 + lymphocytes in vivo. AIDS 11 Suppl. A (1997) S17-S24
172. Perelson A.S., and Nelson P.W. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev. 41 (1999) 3-44
173. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., and Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271 (1996) 1582-1586
174. Persaud D., Ray S.C., Kajdas J., Ahonkhai A., Siberry G.K., Ferguson K., Ziemniak C., Quinn T.C., Casazza J.P., Zeichner S., Gange S.J., and Watson D.C. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res. Hum. Retroviruses 23 (2007) 381-390
175. Persaud D., Siberry G.K., Ahonkhai A., Kajdas J., Monie D., Hutton N., Watson D.C., Quinn T.C., Ray S.C., and Siliciano R.F. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J. Virol. 78 (2004) 968-979
176. Persaud D., Zhou Y., Siliciano J.M., and Siliciano R.F. Latency in human immunodeficiency virus type 1 infection: no easy answers. J. Virol. 77 (2003) 1659-1665
177. Peterson S., Reid A.P., Kim S., and Siliciano R.F. Treatment implications of the latent reservoir for HIV-1. Adv. Pharmacol. 55 (2007) 411-425
178. Phillips A.N. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 271 (1996) 497-499
179. Piatak Jr. M., Saag M.S., Yang L.C., Clark S.J., Kappes J.C., Luk K.C., Hahn B.H., Shaw G.M., and Lifson J.D. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259 (1993) 1749-1754
180. Pierson T., McArthur J., and Siliciano R.F. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 18 (2000) 665-708
181. Pilyugin S.S., Ganusov V.V., Murali-Krishna K., Ahmed R., and Antia R. The rescaling method for quantifying the turnover of cell populations. J. Theor. Biol. 225 (2003) 275-283
182. Poveda E., Briz V., and Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev. 7 (2005) 139-147
183. Prins J.M., et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13 (1999) 2405-2410
184. Ramratnam B., Mittler J.E., Zhang L., Boden D., Hurley A., Fang F., Macken C.A., Perelson A.S., Markowitz M., and Ho D.D. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 6 (2000) 82-85
185. Ramratnam B., Ribeiro R., He T., Chung C., Simon V., Vanderhoeven J., Hurley A., Zhang L., Perelson A.S., Ho D.D., and Markowitz M. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J. Acquir. Immune Defic. Syndr. 35 (2004) 33-37
186. Regoes R.R., Wodarz D., and Nowak M.A. Virus dynamics: the effect of target cell limitation and immune responses on virus evolution. J. Theor. Biol. 191 (1998) 451-462
187. Ribeiro R.M., and Bonhoeffer S. Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl. Acad. Sci. USA 97 (2000) 7681-7686
188. Richman D.D. Antiviral drug resistance. Antiviral Res. 71 (2006) 117-121
189. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., and Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 323 (2009) 1304-1307
190. Rong L., Feng Z., and Perelson A.S. Emergence of HIV-1 drug resistance during antiretroviral treatment. Bull. Math. Biol. 69 (2007) 2027-2060
191. Rong L., Feng Z., and Perelson A.S. Mathematical analysis of age-structured HIV-1 dynamics with combination antiretroviral therapy. SIAM J. Appl. Math. 67 (2007) 731-756
192. Rong L., Gilchrist M.A., Feng Z., and Perelson A.S. Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility. J. Theor. Biol. 247 (2007) 804-818
193. Rong L., and Perelson A.S. Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math. Biosci. 217 (2009) 77-87
194. Rong, L., Perelson, A.S., 2009b. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-1 infected patients on potent therapy. Submitted.
195. Ruff C.T., Ray S.C., Kwon P., Zinn R., Pendleton A., Hutton N., Ashworth R., Gange S., Quinn T.C., Siliciano R.F., and Persaud D. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J. Virol. 76 (2002) 9481-9492
196. Schrager L.K., and D'Souza M.P. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280 (1998) 67-71
197. Sedaghat A.R., Dinoso J.B., Shen L., Wilke C.O., and Siliciano R.F. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc. Natl. Acad. Sci. USA 105 (2008) 4832-4837
198. Sedaghat A.R., Siliciano J.D., Brennan T.P., Wilke C.O., and Siliciano R.F. Limits on replenishment of the resting CD 4 + T cell reservoir for HIV in patients on HAART. PLoS Pathog. 3 (2007) e122
199. Sharkey M.E., Teo I., Greenough T., Sharova N., Luzuriaga K., Sullivan J.L., Bucy R.P., Kostrikis L.G., Haase A., Veryard C., Davaro R.E., Cheeseman S.H., Daly J.S., Bova C., Ellison III R.T., Mady B., Lai K.K., Moyle G., Nelson M., Gazzard B., Shaunak S., and Stevenson M. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 6 (2000) 76-81
200. Sharkey M., Triques K., Kuritzkes D.R., and Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J. Virol. 79 (2005) 5203-5210
201. Siliciano J.D., Kajdas J., Finzi D., Quinn T.C., Chadwick K., Margolick J.B., Kovacs C., Gange S.J., and Siliciano R.F. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD 4 + T cells. Nat. Med. 9 (2003) 727-728
202. Siliciano J.D., Lai J., Callender M., Pitt E., Zhang H., Margolick J.B., Gallant J.E., Cofrancesco Jr. J., Moore R.D., Gange S.J., and Siliciano R.F. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis. 195 (2007) 833-836
203. Siliciano J.D., and Siliciano R.F. A long-term latent reservoir for HIV-1: discovery and clinical implications. J. Antimicrob. Chemother. 54 (2004) 6-9
204. Siliciano R.F. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. Top. HIV Med. 13 (2005) 96-100
205. Simon V., and Ho D.D. HIV-1 dynamics in vivo: implications for therapy. Nat. Rev. Microbiol. 1 (2003) 181-190
206. Sklar P.A., Ward D.J., Baker R.K., Wood K.C., Gafoor Z., Alzola C.F., Moorman A.C., Holmberg S.D., and HIV Outpatient Study (HOPS) Investigators. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 16 (2002) 2035-2041
207. Smith R.J. Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?. Proc. R. Soc. B 273 (2006) 617-624
208. Smith R.J., and Wahl L.M. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. Bull. Math. Biol. 67 (2005) 783-813
209. Sprent J., and Surh C.D. T cell memory. Annu. Rev. Immunol. 20 (2002) 551-579
210. Stafford M.A., Corey L., Cao Y., Daar E.S., Ho D.D., and Perelson A.S. Modeling plasma virus concentration during primary HIV infection. J. Theor. Biol. 203 (2000) 285-301
211. Stanley S.K., Ostrowski M.A., Justement J.S., Gantt K., Hedayati S., Mannix M., Roche K., Schwartzentruber D.J., Fox C.H., and Fauci A.S. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N. Engl. J. Med. 334 (1996) 1222-1230
212. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., Stryker R., Johnson P., Labriola D.F., Farina D., Manion D.J., and Ruiz N.M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N. Engl. J. Med. 341 (1999) 1865-1873
213. Stevenson M. HIV-1 pathogenesis. Nat. Med. 9 (2003) 853-860
214. Strain M.C., Gunthard H.F., Havlir D.V., Ignacio C.C., Smith D.M., Leigh-Brown A.J., Macaranas T.R., Lam R.Y., Daly O.A., Fischer M., Opravil M., Levine H., Bacheler L., Spina C.A., Richman D.D., and Wong J.K. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc. Natl. Acad. Sci. USA 100 (2003) 4819-4824
215. Strain M.C., Little S.J., Daar E.S., Havlir D.V., Gunthard H.F., Lam R.Y., Daly O.A., Nguyen J., Ignacio C.C., Spina C.A., Richman D.D., and Wong J.K. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 191 (2005) 1410-1418
216. Tobin N.H., Learn G.H., Holte S.E., Wang Y., Melvin A.J., McKernan J.L., Pawluk D.M., Mohan K.M., Lewis P.F., Mullins J.I., and Frenkel L.M. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J. Virol. 79 (2005) 9625-9634
217. Tough D.F., and Sprent J. Turnover of naive- and memory-phenotype T cells. J. Exp. Med. 179 (1994) 1127-1135
218. Unutmaz D., Pileri P., and Abrignani S. Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J. Exp. Med. 180 (1994) 1159-1164
219. Verhofstede C., Noë A., Demecheleer E., De Cabooter N., Van Wanzeele F., Van Der Gucht B., Vogelaers D., and Plum J. Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 35 (2004) 473-483
220. Verhofstede C., Wanzeele F.V., Van Der Gucht B., De Cabooter N., and Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 13 (1999) 2541-2546
221. Wahl L.M., and Nowak M.A. Adherence and drug resistance: predictions for therapy outcome. Proc. R. Soc. London B 267 (2000) 835-843
222. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H., Saag M.S., and Shaw G.M. Viral dynamics in human-immunodeficiency-virus type-1 infection. Nature 373 (1995) 117-122
223. Weinberger L.S., Burnett J.C., Toettcher J.E., Arkin A.P., and Schaffer D.V. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122 (2005) 169-182
224. Wodarz D. Killer Cell Dynamics: Mathematical and Computational Approaches to Immunology (2007), Springer, Berlin
225. Wodarz D., May R.M., and Nowak M.A. The role of antigen-independent persistence of memory cytotoxic T lymphocytes. Int. Immunol. 12 (2000) 467-477
226. Wodarz D., and Nowak M.A. CD8 memory, immunodominance, and antigenic escape. Eur. J. Immunol. 30 (2000) 2704-2712
227. Wodarz D., and Nowak M.A. Mathematical models of HIV pathogenesis and treatment. Bioessays 24 (2002) 1178-1187
228. Wong J.K., Hezareh M., Günthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., and Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278 (1997) 1291-1295
229. Wu H., Huang Y., Acosta E.P., Rosenkranz S.L., Kuritzkes D.R., Eron J.J., Perelson A.S., and Gerber J.G. Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J. Acquir. Immune Defic. Syndr. 39 (2005) 272-283
230. Wu H., Zhu H., Miao H., and Perelson A.S. Parameter identifiability and estimation of HIV/AIDS dynamic models. Bull. Math. Biol. 70 (2008) 785-799
231. Ylisastigui L., Archin N.M., Lehrman G., Bosch R.J., and Margolis D.M. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18 (2004) 1101-1108
232. Zhang L., Chung C., Hu B.S., He T., Guo Y., Kim A.J., Skulsky E., Jin X., Hurley A., Ramratnam B., Markowitz M., and Ho D.D. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J. Clin. Invest. 106 (2000) 839-845
233. Zhang H., Dornadula G., Beumont M., Livornese Jr. L., Van Uitert B., Henning K., and Pomerantz R.J. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N. Engl. J. Med. 339 (1998) 1803-1809
234. Zhang Z.Q., Notermans D.W., Sedgewick G., Cavert W., Wietgrefe S., Zupancic M., Gebhard K., Henry K., Boies L., Chen Z., Jenkins M., Mills R., McDade H., Goodwin C., Schuwirth C.M., Danner S.A., and Haase A.T. Kinetics of CD 4 + T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc. Natl. Acad. Sci. USA 95 (1998) 1154-1159
235. Zhang L., Ramratnam B., Tenner-Racz K., He Y., Vesanen M., Lewin S., Talal A., Racz P., Perelson A.S., Korber B.T., Markowitz M., and Ho D.D. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340 (1999) 1605-1613
236. + T cells. Science 286 (1999) 1353-1357
237. Zhu T., Muthui D., Holte S., Nickle D., Feng F., Brodie S., Hwangbo Y., Mullins J.I., and Corey L. Evidence for human immunodeficiency virus type 1 replication in vivo in CD 14 (+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J. Virol. 76 (2002) 707-716